Charles River Laboratories has joined up with FibroBiologics to manufacture the company’s spheroids for clinical trials in multiple sclerosis (MS) and several other conditions.
The spheroids are groups of fibroblast cells arranged in a three-dimensional (3D) structure that more closely resemble how cells organize in living tissues. Fibroblasts are abundant in connective tissue and can regenerate damaged tissues, including nerve cell damage in MS.
“We are proud to discuss opportunities to work with Charles River, a global leader in cell and gene therapy development and manufacturing, as we look to advance our unique fibroblast-based spheroids into the clinic,” Pete O’Heeron, FibroBiologics’ founder and CEO, said in a company press release…read full story HERE.